NCT06720064 Care Bundle Containing Chlorhexidine Dressing on Port Catheter and Central Venous Catheters
| NCT ID | NCT06720064 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dokuz Eylul University |
| Condition | Pediatric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-05-07 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-05-07 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In order to provide treatment in pediatric hematology-oncology patients, in some cases a central venous catheter is required in children. The most important situation to pay attention to when using a central venous catheter is "Central line-associated bloodstream infections". These infections are infections that develop after admission to the hospital and are not in the incubation period at the time of admission, or although they usually develop in the hospital 48-72 hours after hospitalization, they can sometimes appear after discharge. Central line-associated bloodstream infections significantly increase morbidity and mortality. In this context, the effect of using a care bundle containing chlorhexidine dressing on port catheter and central venous catheter-related bloodstream infections in pediatric cancer patients was examined.
Eligibility Criteria
Inclusion Criteria: * The child is receiving inpatient treatment at the Hematology and Oncology unit and hematopoietic stem cell transplantation unit * The child has a diagnosis of hematological or oncological cancer * The child's age range is between 1 and 17 * Having a port catheter inserted and no early complications have occurred * The child agrees to participate in the study voluntarily * The parent agrees to participate in the study voluntarily * Obtaining the consent form from the child and parent * He has been in the hospital for more than 48 hours Exclusion Criteria: * Have a systemic infection.
Contact & Investigator
Gulcin Ozalp Gerceker, Assoc. Prof.
PRINCIPAL INVESTIGATOR
Dokuz Eylul University
Frequently Asked Questions
Who can join the NCT06720064 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, up to 17 Years, studying Pediatric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06720064 currently recruiting?
Yes, NCT06720064 is actively recruiting participants. Visit ClinicalTrials.gov or contact Dokuz Eylul University to inquire about joining.
Where is the NCT06720064 trial being conducted?
This trial is being conducted at Izmir, Turkey (Türkiye).
Who is sponsoring the NCT06720064 clinical trial?
NCT06720064 is sponsored by Dokuz Eylul University. The principal investigator is Gulcin Ozalp Gerceker, Assoc. Prof. at Dokuz Eylul University. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.